EraCal Therapeutics: EraCal Therapeutics enters into research collaboration with Novo Nordisk

The research collaboration combines EraCal's phenotypic zebrafish screening platform with Novo Nordisk's expertise within pharmaceutical peptides and metabolic diseases and will contribute to the discovery of novel drug candidates for the treatment of obesity. The decision of the big Pharma company represents a major confirmation of the broad applicability of EraCal's platform to different groups of therapeutics.